The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis
- https://doi.org/10.2991/ahsr.k.210115.114How to use a DOI?
- Covid-19, Remdesivir, Ruxolitinib, Systemic Review, Meta-Analysis
The treatment regimen in severe Covid-19 patients has several types of therapies. However, there is uncertainty about which therapies are more effective in the covid-19 weight category. In June 2020, the study was conducted with keyword search [REMDESIVIR] [RUXOLITINIB] [COVID19] in 2010-2020 using PUBMED.gov. This study used rct (randomization controller trial) method with the theme: the comparison of the effectiveness use of Remdesivir with Ruxolitinib on Covid-19. From the results of the analysis using forest plot obtained, there was a significant difference in the administration of Remdesivir therapy with Ruxolitinib on the improvement from covid-19 on day 7 (1.26 CI 95% 0.41 to 3.86) and day 14 (RR 1.26 CI 95% 0.41 to 3.86). Ruxolitinib therapy is more effective than Remdesivir applied for Covid-19 patients.
- © 2021, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Nuriyatul Fhatonah AU - Ma’sum AU - Zenith Putri Dewianti AU - Nur’aini AU - Nita Rusdiana PY - 2021 DA - 2021/01/16 TI - The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis BT - Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020) PB - Atlantis Press SP - 604 EP - 607 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.210115.114 DO - https://doi.org/10.2991/ahsr.k.210115.114 ID - Fhatonah2021 ER -